

The image features a background of a laboratory or pharmacy setting. In the foreground, several small, amber-colored glass vials are lined up on a metal tray. The background is filled with out-of-focus lights, creating a bokeh effect with various colors like white, blue, and pink. A large, stylized green leaf graphic is positioned in the upper left corner, partially overlapping the logo.

little  
green  
pharma

Investor Presentation  
22 July 2020

# Disclaimer



## NOT AN OFFER OF SECURITIES

This document has been independently prepared by Little Green Pharma Ltd ACN 615 586 215 (LGP) and is provided for informational purposes only.

This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction (in particular, the United States), or a securities recommendation. This document is not a prospectus, product disclosure statement or other offering document under Australian law or any other law, and will not be lodged with the Australian Securities and Investments Commission.

## Summary information

This document contains a summary of information about LGP and its activities that is current as at the date of this document. The information in this document is general in nature and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (Corporations Act).

## No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by LGP or any of its affiliates for updating any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which LGP and any of its affiliates or advisers may become aware.

## Forward looking statement

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated.

Statements contained in this document, including but not limited to those regarding the possible or assumed future costs, performance, dividends, returns, revenue, exchange rates, potential growth of LGP, industry growth or other projections and any estimated company earnings are or may be forward looking statements. Forward-looking statements can generally be identified by the use of words such as 'project', 'foresee', 'plan', 'expect', 'aim', 'intend', 'anticipate', 'believe', 'estimate', 'may', 'should', 'will' or similar expressions. These statements relate to future events and expectations and as such involve known and unknown risks and significant uncertainties, many of which are outside the control of LGP. Actual results, performance, actions and developments of LGP may differ materially from those expressed or implied by the forward-looking statements in this document.

Such forward-looking statements speak only as of the date of this document. There can be no assurance that actual outcomes will not differ materially from these statements. To the maximum extent permitted by law, LGP and any of its affiliates and their directors, officers, employees, agents, associates and advisers:

- disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions;
- do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this document, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and
- disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).

## Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

## Information in this document is confidential

This document and the information contained within it are strictly confidential and are intended for the exclusive benefit of the persons to whom it is given. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of LGP. By receiving this document, you agree to keep the information confidential, not to disclose any of the information contained in this document to any other person and not to copy, use, publish, record or reproduce the information in this document without the prior written consent of LGP, which may be withheld in its absolute discretion.

## Acceptance

By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.

# Corporate Overview

## Little Green Pharma Overview

- Vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution
- Indoor cultivation facility in WA and exclusive partnership with GMP-licensed pharmaceutical manufacturer
- Supplies medical-grade cannabis products to Australian and overseas markets

## Capital structure


Current Share Price <sup>1</sup>	\$0.35
Shares Outstanding <sup>2,3</sup>	133,573,069
Options and Performance Rights on Issue	21,851,536
Market Capitalisation (undiluted) <sup>1</sup>	~\$46.7 million
Net Cash (30 June 2020)	~\$4.3 million
Enterprise Value	~\$42.4 million

- As at 30 June 2020
- 25,634,219 shares are escrowed 6-12 months from date of listing (20 Feb 2020)
- 54,034,703 shares are escrowed 24 months from date of listing (20 Feb 2020)
- As at 30 June 2020

## Top 5 Shareholders<sup>4</sup>

Shareholder	Shareholding	Ownership
Elixer Ltd	30.8m	23.1%
Fleta Solomon (Managing Director)	19.6m	14.7%
Angus Caithness (Executive Director)	5.7m	4.3%
GSCO - ECA Resource Geologic Partners	5.4m	4.0%
TIGA Trading Pty Ltd	3.4m	2.5%
Top 20 shareholders	84.9m	63.5%
Board ownership	26.7m	20.1%

## Register Breakdown<sup>4</sup>



We believe it's necessary to produce high-quality cannabis medicines now and develop meaningful innovative delivery systems for the future to improve patient outcomes and solve real patient problems.


We are passionate about transforming lives. This drives our desire to grow and produce quality cannabis medicines that are safe, effective and affordable. It's the heart of everything we do and defines our culture. This is our purpose – to reimagine cannabis medicine and do extraordinary things for our patients.

We are proud of what we've done and where we're going.

**We are Little Green Pharma.**

# Our Business Model Captures Value

LGP operates across the medicinal cannabis supply chain



1. LGP has an exclusive agreement with a TGA-GMP licensed medicinal cannabis manufacturer who may only terminate the agreement after 22 November 2023 on 12 months' notice.



# Redefining the Medicinal Cannabis Industry

- ✓  Generating revenue since August 2018
- ✓  First Australian company to produce and export local cannabis medicines
- ✓  One of only a few companies globally with finished GMP<sup>1</sup> cannabis medicines
- ✓  Cultivation facility capacity up to 110,000 bottles equivalent p/a
- ✓  Construction of own manufacturing facility underway
- ✓  Developing unique drug delivery system and product offering
- ✓  Lean business model – strict focus on cash and capital management

1. GMP – Good Manufacturing Practice (EU compliant). This is a prerequisite to sell into Europe. The TGA GMP certification is held by our contracted manufacturer

# Growth Strategy

Little Green Pharma has existing sales and a clear pathway to increasing margins and driving significant revenue growth in domestic & international markets



1

Proven sales in Australia

Currently selling four LGP-branded THC and CBD medicines in Australia with future products in the proposed R&D pipeline



2

Clear pathway to international sales

Sales agreements with distributors in the UK and Germany for the import and distribution of LGP's cannabis medicines



3

Patient access and product innovation

Driving patient access through education platforms. Clinical investigations & research projects underway to develop innovative new delivery systems



Why these are strategically important:

Sales in Australia demonstrate market validity and generate immediate cash flow




Commercial sales volumes in international markets is the primary target to realise longer-term profits



Our focus is on producing high-quality market-meeting cannabis medicines now and developing unique delivery systems for patients in the future

# Track Record of Growing Patient Access

Strong growth in sales and patients using LGP products in Australia





# Capability to Support Growth Strategy

Our capability to deliver volumes extends beyond our existing cultivation footprint



## Cultivation & Raw Biomass

- ✓ Cultivation capacity is 110,000 bottles equivalent of cannabis oils
- ✓ Optional capacity to double production with further expansion
- ✓ Established channels of high quality third party raw material



## Manufacturing Capability

- ✓ Volume manufacturing capability with third party TGA-GMP licensed manufacturer<sup>1</sup>
- ✓ Construction of own manufacturing facility underway (currently ODC licenced)



1. LGP has an exclusive agreement with a TGA-GMP certified medicinal cannabis manufacturer who may only terminate the agreement after 22 November 2023 on 12 months' notice.

# News Flow – making solid progress

Significant commercial progress as LGP executes growth strategy



Completion of cultivation facility expansion



First product delivered to Astral Health in the UK



Further expansion of product line with new *LGP Classic CBD 50* product



First large commercial quantity delivered to Astral Health in the UK



Final permit granted and first crop planting at expanded facility



Fulfilment of CC Pharma order into Germany (2,400 bottles)



Commissioning of own manufacturing facility



Commencement of first ethics approved large scale study



Delivery of first products into South America



Delivery of first flower products to Germany

# Australian medicinal cannabis oils

2018  
First  
Australian  
products





## LGP Head Office

PO Box 690, West Perth  
Western AUSTRALIA 6872

1300 703 999 | +61 8 6280 0050

[info@littlegreenpharma.com.au](mailto:info@littlegreenpharma.com.au)